A conversation with Sayeh Lavasani, MD, MS, a medical oncologist specializing in breast cancer at the City of Hope Comprehensive Cancer Cente, in Duarte, California, who discusses how clinical pathways are developed and used at the cancer center, how the pathways for patients with HER2-low breast cancer are utilized, recent updates in the HER2-low treatment landscape, the challenges and level of evidence needed to incorporate new therapeutic approaches into the clinical pathway, and the challenges and crafty balancing that’s needed between standardizing treatment decisions across the population and optimizing care for individual patients.